FLUIDDA has announced that it will meet with the FDA on January 17, 2014 to present its Functional Respiratory Imaging (FRI) technology for screening respiratory drugs. The FDA is evaluating FRI as part of its critical path initiative, which includes the development of new biomarkers.
The technology combines CT scans with flow simulations, creating patient-specific 3D models for visualization of airway resistance, airflow distribution, and aerosol deposition. According to the company, the accuracy of the technology results in the possibility of clinical trials involving significantly fewer patients.
FLUIDDA CEO Jan De Backer said, “This invitation is very important for FLUIDDA. Positive feedback from FDA regarding FRI will be a strong signal for pharmaceutical companies to include FRI endpoints in their clinical trials.”
Read the FLUIDDA press release.
